<DOC>
	<DOC>NCT00090077</DOC>
	<brief_summary>To investigate safety, tolerability and antiviral activity in Non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced HIV-1 infected patients</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion criteria: CD4 cell count greater than or equal to 200 cells/mm3. HIV1 RNA &gt;2000 copies/mL. Must have history of NNRTI treatment with subsequent failure and documented evidence of an NNRTIassociated mutation or a phenotype displaying reduced activity to efavirenz, nevirapine or delavirdine. Normal resting 12lead electrocardiogram. Exclusion criteria: Any history of seizure, CNS toxoplasmosis infection, or any CNS (central nervous system) lesion. Chronic diarrhea (&gt;3 loose stools/day). An active CDC Category C disease (1993), except cutaneous Kaposi's Sarcoma (KS) not requiring systemic therapy during the trial. Less than 4 weeks since stopping antiretroviral therapy (ART) therapy prior to Day 1. Any acute laboratory abnormality. Positive for HCV antibody or HepBsAG. Active infections requiring therapy in the previous 4 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>GW695634G</keyword>
	<keyword>GW695634X</keyword>
	<keyword>GW678248X</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>NNRTI</keyword>
	<keyword>HIV</keyword>
</DOC>